10x Genomics, Inc. Federal Income Tax Expense (Benefit), Continuing Operations
10x Genomics, Inc. (TXG) reported Federal Income Tax Expense (Benefit), Continuing Operations of -$37.32 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-02-13
- 10x Genomics, Inc. federal income tax expense (benefit), continuing operations for fiscal 2024 was -$37.32M.
- 10x Genomics, Inc. federal income tax expense (benefit), continuing operations for fiscal 2023 was -$52.24M.
- 10x Genomics, Inc. federal income tax expense (benefit), continuing operations for fiscal 2022 was -$34.01M.
- 10x Genomics, Inc. federal income tax expense (benefit), continuing operations for fiscal 2021 was -$11.28M.
| Period end | Federal Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2024-12-31 | -$37.32M 10-K · filed 2026-02-13 |
| 2023-12-31 | -$52.24M 10-K · filed 2026-02-13 |
| 2022-12-31 | -$34.01M 10-K · filed 2025-02-13 |
| 2021-12-31 | -$11.28M 10-K · filed 2024-02-15 |
| 2020-12-31 | -$112.24M 10-K · filed 2023-02-16 |
| 2019-12-31 | -$6.52M 10-K · filed 2022-02-18 |
| 2018-12-31 | -$23.60M 10-K · filed 2020-02-27 |